BrainChild Bio announced a $116 million Series A on September 8, 2026, backed by an undisclosed private family fund and foundation, Seattle Children's and WRF Capital. The capital funds a pivotal Phase 2 trial of lead candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG), a childhood brainstem cancer.
BrainChild Bio raises $116M Series A for pediatric brain-cancer therapy
A large Series A anchored by a hospital system and mission-aligned family capital shows deep-tech and biotech founders that strategic and philanthropic backers can lead, not just follow, priced rounds.
Source: Fierce Biotech
More that helps you.
AI health startup Forus raises $150M at $3B value to automate drug access
Forus (formerly Tandem) raised a $150 million Series C at a $3 billion valuation announced September 8, 2026, led by Bain Capital Ventures with Accel, Thrive Capital, General Catal…
Ridgeline raises $250M Series E at $1.425B for AI-native investment platform
Ridgeline, founded by Workday and PeopleSoft founder Dave Duffield, raised a $250M Series E on Sept 16, 2026 at a $1.425 billion valuation, with participation from Motley Fool Vent…
Hong Kong's Qupital secures $300M to fund e-commerce sellers with AI underwriting
Qupital announced roughly $300 million in combined equity and asset-backed financing on September 13, 2026, with M Capital leading and MUFG and Quester Capital participating. It pr…
Fleet-management platform Motive lands $1.3B in growth financing
Motive, a fleet management and logistics operations platform, raised $1.3 billion in private-equity growth financing led by General Catalyst, per Crunchbase's week-ending September…
Get briefs like this tuned to you.
In the app, Founder Briefs are personalized to your country, industry and stage, and you can save the ones that matter.
See plans →